ALSO NOTED: Baxter selling Transfusion Therapies; Lumigen sells for $185M; and much more...

> Baxter International announced it is selling Transfusion Therapies to Texas Pacific Group for $540 million. Release

> Beckman Coulter is buying Lumigen for $185 million. Lumigen makes chemicals used in research work. Report

> Cambridge, MA-based Xanthus has in-licensed a cancer therapy from Schering for an undisclosed amount of money and milestones. Xanthus gains the U.S. rights to oral fludarabine, which has been approved in Europe for certain types of leukemia. Xanthus says the therapy may be useful against other cancers as well. Report

> The FDA has granted fast track designation to Allos Therapeutics' antifolate PDX (pralatrexate) for the treatment of patients with T-cell lymphoma. Report

> Las Vegas economic development authorities have set their sights on recruiting biotech companies from New Jersey. Report

> Syngenta's fungicide Revus has been approved in Austria and South Korea. Report

> Cellgate has started a Phase Ib trial of CGC-11047 in combination with four standard chemotherapeutics in patients with advanced solid tumor malignancies or lymphomas. Release

And Finally… European doctors routinely advise patients to take prescription fish oil after a heart attack. But the therapy--despite data supporting its effectiveness--isn't even approved for use in the U.S. Article

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.